MAPT and early-onset autosomal dominant Alzheimer disease: Key biomarkers such as beta-amyloid (Aβ), tau protein, α-synuclein, and inflammatory cytokines are widely used to assess disease progression in Alzheimer’s disease (AD), Parkinson’s disease (PD), depression, and anxiety [39,40,41,42,43,44,45].